Sonnet BioTherapeutics Holdings, Inc. (SONN) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti

Sonnet BioTherapeutics Holdings, Inc. (SONN) korporativ emblemasi va logotipi

Sonnet BioTherapeutics neo-plazmalarga qarshi kurashish uchun FHAB platformasi orqali maqsadli sitokin yetkazib berish tizimini ishlab chiqmoqda. Kompaniya hozirda yangi dori vositalari bo'yicha qimmat turadigan tadqiqotlarni olib borish uchun mavjud kapitalini yo'naltirmoqda. Operatsion foyda mavjud emasligi sababli, ishlab chiqish grantlar va yangi aksiyalar emissiyasiga tayanadi, bunda ko'rsatkich -0.60 darajasida turibdi. Quyidagi narxlar grafigi ushbu biotexnologik loyihaning bozor dinamikasini aniq tarzda aks ettiradi.

SONN sonnetbio.com: Narx-foyda koeffitsiyenti 04.07.2022 - 13.12.2025 oraligʻida

Sonnet BioTherapeutics kompaniyasining tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning har tomonlama tahlili:SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics ishlab chiqargan mahsulot

Investorlar aktivning haddan tashqari sotib olinganligini aniqlash uchun ushbu ko'rsatkichdan foydalanib, bozor kapitalizatsiyasining sof foydaga nisbatini orqali investitsiyalarning qoplash muddatini baholaydilar. Sof foydaga asoslangan P/E ko'rsatkichi tahlil qilinganda, shaxsiy zavodlarning yo'qligi va tadqiqotlarning autsorsing qilinishi Sonnet BioTherapeutics (SONN) uchun kapital xarajatlarni qanday qilib minimallashtirishi, bu esa yakuniy daromadlilikka va aksiyalarning fundamental qiymatiga bevosita ta'sir qilishi ayon bo'ladi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning foydaga nisbati ImmunityBio IBRX|P/E multiplikatori IMCR|Janux Therapeutics (JANX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Arcus Biosciences Inc - Narx-foyda koeffitsiyenti|Zymeworks (ZYME) - Kapitalizatsiyaning foydaga nisbati|TNGX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati IOVA (Iovance Biotherapeutics, Inc.)|IMTX: P/E multiplikatori|XNCR - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati compasstherapeutics.com|Narx-foyda koeffitsiyenti replimune.com (REPL)|Narxning foydaga nisbati Lyell (LYEL)|Narx-foyda koeffitsiyenti Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori Compugen Ltd. CGEN|IOBT - Narxning foydaga nisbati|STRO (sutrobio.com) - Narx-foyda multiplikatori|MiNK Therapeutics, Inc (INKT) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Werewolf Therapeutics (HOWL)|Narx-foyda koeffitsiyenti IMMX|ALXO - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori CUE|Bozor narxining sof foydaga nisbati PDSB|P/E multiplikatori MAIA (MAIA Biotechnology, Inc.)|Kompaniya qiymatining sof foydaga nisbati LIMN|Lava Tx - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NextCure Corporation|Leap Tx (LPTX) - Narxning foydaga nisbati|Intensity Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|SNSE (Sensei Bio) - P/E multiplikatori|P/E multiplikatori Theriva Biologics Inc|Narxning foydaga nisbati gritstonebio.com (GRTS)|P/E multiplikatori Kineta Bio (KA)|NexImmune Inc - Narx-foyda koeffitsiyenti|turnstonebio.com (TSBX) - Kapitalizatsiyaning foydaga nisbati|VCNX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HARP (Harpoon Therapeutics, Inc.)